This year’s Endpoints 11 winners; Monarez testifies to Congress; Eli Lilly’s obesity pill lags; and morenews2025-09-20T10:00:58+00:00September 20th, 2025|Endpoints News|
Novo Nordisk’s ongoing challenges; Summit’s Western data disappoint; Eli Lilly offers free AI access to startups; and morenews2025-09-13T10:00:40+00:00September 13th, 2025|Endpoints News|
Maraganore, Meanwell team up; FDA publishes CRLs; Endpoints 11: Where are they now?; and morenews2025-09-06T10:00:53+00:00September 6th, 2025|Endpoints News|
Turbulence at the CDC; How Scripps reinvented its financial model; Biopharma’s return to MC4R; and morenews2025-08-30T10:00:18+00:00August 30th, 2025|Endpoints News|
Viking’s obesity readout; George Church lab closer to creating human eggs; Skyhawk gets new pharma partnernews2025-08-23T10:00:09+00:00August 23rd, 2025|Endpoints News|
Bayer bets big on KRAS inhibitor; Treg biotech shuts down; Novartis touts trial wins; and morenews2025-08-16T10:00:43+00:00August 16th, 2025|Endpoints News|
Eli Lilly’s obesity pill data; This week’s Q2 highlights; Biogen’s latest reinvention; and morenews2025-08-09T10:00:37+00:00August 9th, 2025|Endpoints News|
Prasad departs FDA; Merck cuts $3B in costs; Trump renews call for ‘most favored nation’ plan; and morenews2025-08-02T10:00:28+00:00August 2nd, 2025|Endpoints News|
Sarepta fallout continues; MAHA is angry as Loomer points fingers; A CAR-T week in biotech; and morenews2025-07-26T10:00:41+00:00July 26th, 2025|Endpoints News|
Sarepta’s crisis week; Prasad overrides reviewers again; A new study’s clues about Alzheimer’s; and morenews2025-07-19T10:00:57+00:00July 19th, 2025|Endpoints News|
